


The burden of antimicrobial resistance (AMR) in Colombia

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **4,000 lives** have been lost each year since 1990 in Colombia due to AMR.
- In 2021, there were an estimated **4,850 UI (4,020-5,690)** deaths attributable to AMR and **19,600 UI (16,200-23,000)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Klebsiella pneumoniae* resistant to carbapenems and *Streptococcus pneumoniae* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Colombia, a 10% reduction means to decrease the number of deaths associated with AMR to **17,100**, but currently the trend for this country could reach up to **25,400 UI [19,700-31,700]** AMR-associated deaths in 2030.

AMR in Colombia

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Colombia between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Colombia** in 2021, there were an estimated **4,850 UI (4,020-5,690)** deaths attributable to AMR and **19,600 UI (16,200-23,000)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Colombia has the 57th lowest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden rank	Overall susceptible and resistant		Associated		Attributable	
	Staphylococcus aureus 6,000 UI (4,980-7,020)	↑	Escherichia coli 3,800 UI (3,140-4,460)	↑	Staphylococcus aureus 991 UI (788-1,190)	↑
	Escherichia coli 4,140 UI (3,430-4,850)	↑	Staphylococcus aureus 3,730 UI (3,080-4,380)	↑	Klebsiella pneumoniae 871 UI (719-1,020)	↑
	Streptococcus pneumoniae 3,480 UI (2,890-4,070)	↓	Klebsiella pneumoniae 2,990 UI (2,460-3,520)	↑	Escherichia coli 787 UI (624-951)	↑
	Pseudomonas aeruginosa 3,400 UI (2,820-3,980)	↑	Streptococcus pneumoniae 2,430 UI (1,940-2,930)	↓	Pseudomonas aeruginosa 592 UI (456-728)	↑
	Klebsiella pneumoniae 3,290 UI (2,720-3,860)	↑	Pseudomonas aeruginosa 2,270 UI (1,870-2,660)	↑	Streptococcus pneumoniae 513 UI (388-637)	↓
	Acinetobacter baumannii 1,760 UI (1,460-2,070)	↓	Acinetobacter baumannii 1,110 UI (878-1,330)	↓	Acinetobacter baumannii 424 UI (346-502)	↓
	Mycobacterium tuberculosis 1,010 UI (837-1,190)	↓	Enterobacter spp. 651 UI (515-787)	↑	Enterococcus faecium 157 UI (125-190)	↑
	Group A Streptococcus 942 UI (770-1,120)	↑	Enterococcus faecium 597 UI (492-702)	↑	Enterobacter spp. 149 UI (121-177)	↑
	Enterococcus faecalis 927 UI (767-1,090)	↑	Proteus spp. 426 UI (329-523)	↑	Serratia spp. 88 UI (71-104)	↓
	Proteus spp. 876 UI (727-1,030)	↑	Serratia spp. 342 UI (276-407)	↓	Proteus spp. 69 UI (51-87)	↑

Annualized rate of change (1990-2021) <-3% -3% to -1.5% -1.5% to 0% 0% to 1.5% 1.5% to 3% 3% to 5% >5.0%


Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden Rank	Associated		Attributable	
	Escherichia coli TMP-SMX 3,630 UI (2,980-4,280)	↑	Staphylococcus aureus Methicillin 788 UI (601-976)	↑
	Escherichia coli Aminopenicillin 3,150 UI (2,520-3,770)	↑	Klebsiella pneumoniae Carbapenems 391 UI (291-490)	↑
	Staphylococcus aureus Methicillin 2,940 UI (2,230-3,650)	↑	Streptococcus pneumoniae Carbapenems 351 UI (247-456)	↑
	Klebsiella pneumoniae TMP-SMX 2,920 UI (2,390-3,450)	↑	Pseudomonas aeruginosa Carbapenems 298 UI (199-397)	↑
	Staphylococcus aureus Macrolides 2,730 UI (2,190-3,270)	↑	Escherichia coli TMP-SMX 204 UI (115-292)	↑
	Escherichia coli Fluoroquinolones 2,210 UI (1,810-2,610)	↑	Acinetobacter baumannii Carbapenems 191 UI (142-240)	↓
	Klebsiella pneumoniae Carbapenems 1,790 UI (1,460-2,110)	↑	Escherichia coli Carbapenems 170 UI (105-235)	↑
	Streptococcus pneumoniae TMP-SMX 1,740 UI (1,210-2,280)	↓	Klebsiella pneumoniae TMP-SMX 159 UI (80-238)	↑
	Escherichia coli Beta-Lactam/Lactamase Inhib. 1,730 UI (1,380-2,070)	↑	Pseudomonas aeruginosa Fluoroquinolones 140 UI (93-187)	↑
	Klebsiella pneumoniae Aminoglycosides 1,670 UI (1,320-2,030)	↑	Klebsiella pneumoniae Fluoroquinolones 139 UI (93-185)	↑

Annualized rate of change (1990-2021) <-3% -3% to -1.5% -1.5% to 0% 0% to 1.5% 1.5% to 3% 3% to 5% >5.0%

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) lower respiratory infection (excl. COVID) (14,800 UI (12,300-17,400)), bloodstream infections (13,700 UI (11,200-16,100)), peritoneal and intra-abdominal infections (4,680 UI (3,840-5,510)), urinary tract infections and pyelonephritis (4,450 UI (3,670-5,230)) and infections of the skin and subcutaneous systems (2,160 UI (1,740-2,590)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Colombia, people aged under 5 experienced the largest number of deaths associated with AMR in 1990 but this changed by 2021 as the largest number of deaths occurred among the 70+. This indicates that prevention of infections among the under 5 has contributed to the reduction in the number of AMR associated deaths. In 2021, the number of deaths associated with AMR among the 70+ was 11,200 UI (9,280-13,200), whereas the mortality rate per 100,000 was 352 UI (291-413).

Data sources for Colombia

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Colombia by source type

Source type	Years	Sample size	Sample size units
Antibiotic use	1990-2021	1,014	Study-year datapoints
Microbial or laboratory data without outcome	1990-2021	20,723,059	Isolates
Microbial or laboratory data with outcome	1990-2021	96,361	Isolates
Literature studies	1990-2021	14,448	Cases/isolates/susceptibility tests
Single drug resistance profile data	1990-2021	283,200	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care's Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>